HC Wainwright Has Pessimistic Outlook of uniQure Q2 Earnings

uniQure (NASDAQ:QURE) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for uniQure in a research note issued to investors on Tuesday, May 13th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will earn ($0.73) per share for the quarter, down from their previous forecast of ($0.72). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s FY2025 earnings at ($3.11) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.66) EPS and Q4 2026 earnings at $0.09 EPS.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million.

QURE has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of uniQure in a report on Monday. Wells Fargo & Company decreased their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Guggenheim reissued a “buy” rating and set a $28.00 price objective on shares of uniQure in a research note on Monday. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.82.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $13.25 on Friday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $725.78 million, a PE ratio of -2.67 and a beta of 0.10. The company’s fifty day moving average is $12.28 and its 200 day moving average is $12.23. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 6,717 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now owns 580,795 shares in the company, valued at $6,574,599.40. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares of the company’s stock, valued at $2,240,441.70. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Avoro Capital Advisors LLC bought a new position in uniQure in the fourth quarter worth $38,410,000. Vestal Point Capital LP grew its position in shares of uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after buying an additional 1,767,572 shares during the period. RTW Investments LP increased its stake in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after acquiring an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. lifted its position in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after acquiring an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC bought a new stake in uniQure during the fourth quarter worth about $13,245,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.